Google NewsImugene (ASX:IMU): Could the Next Clinical or Commercial Catalyst Spark a Major Re-Rating? - Kalkine
Imugene (ASX:IMU): Could the Next Clinical or Commercial Catalyst Spark a Major Re-Rating? Kalkine
Imugene (IMU) News
Latest articles and price-sensitive announcements with AI sentiment classification.
_07_03_2026_03_50_21_133108.jpg&w=3840&q=65)
KalkineImugene Directors Kim Drapkin, Jakob Dupont, and Lesley Russell Report Expiry of $4.012 Options on August 31, 2026
Imugene Limited (ASX:IMU) has announced that directors Kim Drapkin, Jakob Dupont, and Lesley Russell each had options expiring on 31 August 2026 lapse unexercised, as detailed in Change of Director's Interest Notices filed with the ASX under listing rule 3.19A.2. Key Points Directors Drapkin, Dupont, and Russell held options priced at $4.012 expiring on 31 August 2026, which expired without exercise or conversion. Kim Drapkin disposed of 3,502 options and currently holds zero options of that ...
ASXApplication for quotation of securities - IMU
other announcement
Change of Director's Interest Notice x4
director_dealing announcement
Notice under section 708A(12C)(e) of the Corporations Act
other announcement
Imugene (ASX:IMU) Shares Reach 52-Week Low as Biotechnology Stock Remains Under Market Focus - Kalkine
Imugene (ASX:IMU) Shares Reach 52-Week Low as Biotechnology Stock Remains Under Market Focus Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Imugene (ASX:IMU) Announces CEO Transition While Azer-cel Trial Reaches Another Milestone - Kalkine
Imugene (ASX:IMU) Announces CEO Transition While Azer-cel Trial Reaches Another Milestone Kalkine
Third response in concurrent BTKi Cohort of azer-cel Trial
other announcement
Imugene Limited Announces Expiry of 5,845 Restricted Stock Units Due to Unmet Conditions
Imugene Limited (IMU), an Australian biotechnology firm, has informed the ASX about the expiry of 5,845 restricted stock units following the failure to meet attached conditions. These units lapsed on 15 June 2026 after the stipulated requirements were not fulfilled or became impossible to satisfy. This event represents a minor modification within the company’s overall capital structure, which remains largely unchanged. Key Points Imugene Limited (IMU) is an Australian biotech company listed...
Notice of Extraordinary General Meeting/Proxy Form
other announcement
$11.1 Million Placement Completed to Advance azer-cel
capital_raise announcement
Change of Director's Interest Notice x5
director_dealing announcement
Clinical Trial Progress Sparks Fresh Interest in Imugene (ASX: IMU) Shares - Kalkine
Clinical Trial Progress Sparks Fresh Interest in Imugene (ASX: IMU) Shares Kalkine
New Complete Response in the Concurrent BTKi azer-cel Cohort
other announcement
First Complete Response in Concurrent BTKi azer-cel Cohort
other announcement
Imugene (ASX:IMU): Biotech Stock Rockets as FDA Fast Track News Ignites Investor Excitement - Kalkine
Imugene (ASX:IMU): Biotech Stock Rockets as FDA Fast Track News Ignites Investor Excitement Kalkine
Azer-cel Granted FDA Fast Track Designation for CLL and MZL
other announcement
azer-cel CAR-T naive data presented at ASCO Annual Meeting
other announcement
First Patient in BTKi Combination Cohort of azer-cel study
other announcement
Imugene Advances Cancer Research With Azer-cel Progress
Highlights Azer-cel trial shows encouraging patient responses Study focuses on difficult blood cancer cases Imugene expands immunotherapy research momentum Imugene continues advancing its immuno-oncology pipeline as fresh clinical findings from its azer-cel study highlight encouraging treatment activity in difficult blood cancer cases. Clinical-stage immuno-oncology company Imugene (ASX:IMU) has drawn market attention after releasing fresh clinical findings linked to its azer-cel therap...
Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
other announcement
Change of Director's Interest Notice - PH
director_dealing announcement
Change of Director's Interest Notice - LC
director_dealing announcement
Notice under section 708A(12C)(e) of the Corporations Act
other announcement
Listed Options Top Holders & Holdings Range Report
other announcement